UNSPSC 51433102: Spirapril

This classification denotes an ace inhibitor with the molecular formula C22H30N2O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 96U2K78I3V, chemically known as 1,4-dithia-7-azaspiro(4,4)nonane-8-carboxylic acid, 7-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, (8s-(7(r*(r*)),8r*))- but generally known as spirapril, which bears US NIH Compound Identifier 91736. European Medicines Agency schedules Spirapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10620MIG.

UNSPSC 51433102 Spirapril is a Commodity code covering pharmaceutical products, specifically prescription medications and active pharmaceutical ingredients state and local governments procure for emergency medical services, hospital systems, and health and human services programs. State and local buying under this code centers on sealed-bid purchases of individual medication line items with firm pricing, volume specifications, expiration-date warranties, and delivery timelines measured in days to weeks. The issuing bodies soliciting under this code include municipal fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions and government facilities.

Recent activity shows three representative opportunities spanning different procurement models and geographies. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (due April 8, 2026) requesting 370 units of Labetalol HCl 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue, with an estimated contract value of $40,000.00 and a Small Local Business Enterprise bid discount of up to 5 percent. The Texas Health and Human Services Commission issued RFI HHS0017013 (due April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities as part of a broader Therapeutic Pharmacy Initiative. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers to state and local government facilities in Minnesota and Oregon, with contract effectiveness July 1, 2026. Recent activity concentrates in Florida, Texas, and Minnesota, with cooperative purchasing vehicles extending reach across multiple states.